SCHEMBL682707

SCHEMBL682707

COc1ccc2c(C(C)=O)c(C)nn2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.45
MAPT P10636 4/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 2/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HPGD P15428 1/20 0.41
HIF1A Q16665 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
POLB P06746 2/20 0.40
PKM P14618 1/20 0.40
MDM2 Q00987 1/20 0.40
PDE4D Q08499 1/20 0.40
FPR1 P21462 1/20 0.39
FPR2 P25090 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.37
NTRK1 P04629 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684212 0.87 POLB (0.48) NPC1MAPTHTTLMNAMEN1
SCHEMBL7427855 0.81 ALDH1A1 (0.36) NPC1MAPTHTTLMNAKMT2A
SCHEMBL682698 0.80 GAA (0.38) NPC1MAPTHTTLMNAMEN1
SCHEMBL6822071 0.79 EGFR (0.46) MAPTHTTMEN1KMT2AALDH1A1
SCHEMBL683508 0.78 ALDH1A1 (0.39) MAPTHTTMEN1KMT2ANPSR1
SCHEMBL22147873 0.75 ALDH1A1 (0.42) MAPTHTTMEN1KMT2AHPGD
SCHEMBL17323234 0.72 LCK (0.46) NPC1MAPTHPGDPKMRAB9A
SCHEMBL682721 0.71 MEN1 (0.59) NPC1MAPTHTTMEN1KMT2A
SCHEMBL5848990 0.71 ALDH1A1 (0.51) NPC1MAPTMEN1KMT2AHPGD
SCHEMBL20620683 0.69 HPGD (0.42) MAPTHTTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
EP-0368343-B1 AMELIORATING COMPOSITION FOR DYSMNESIA KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1993-06-30 EP disclosed
US-4990516-A Pyrazolo (1,5-a)pyridine derivatives KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1991-02-05 US disclosed
EP-0368343-A2 Ameliorating composition for dysmnesia KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1990-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF NPC1 2460/4885MAPT 1368/4885HTT 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.